Home / Health / Glenmark Pharma gets nod to launch favipiravir for Covid-19 patients

Glenmark Pharma gets nod to launch favipiravir for Covid-19 patients

Glenmark is conducting phase-3 clinical trials; drug has got restricted emergency use

Premium

In the first week of June after Russia approved use of avifavir, a derivative of Favipiravir, for treatment of Covid-19, India worked to ensure the antiviral drug is available here, too, soon

Sohini Das Mumbai

3 min read Last Updated : Jun 19 2020 | 11:48 PM IST

Antiviral oral drug favipiravir on Friday received the nod from the Indian drug regulator to be launched in the domestic market to treat mild-to-moderate patients of Covid-19.

Mumbai-based drug major Glenmark Pharmaceuticals is conducting phase-III clinical trials to assess the drug’s efficacy on Covid-19 patients. The drug may be available as early as next week, claimed sources.

India had given nod to Gilead’s remdesivir some time back based on the clinical trial data presented by the company.

The Drug Controller General of India (DCGI) has given manufacturing and marketing approval to Glenmark to launch oral favipiravir (under brand name FabiFlu) to treat mild

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in